Your browser doesn't support javascript.
loading
Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation.
Chapuy, Claudia I; Kaufman, Richard M; Alyea, Edwin P; Connors, Jean M.
Affiliation
  • Chapuy CI; From the Dana-Farber Cancer Institute at St. Elizabeth's Medical Center (C.I.C.), Blood Bank, Department of Pathology (R.M.K.), and the Division of Hematology (J.M.C.), Brigham and Women's Hospital, and the Department of Medical Oncology, Dana-Farber Cancer Institute (E.P.A.) - all in Boston; and th
  • Kaufman RM; From the Dana-Farber Cancer Institute at St. Elizabeth's Medical Center (C.I.C.), Blood Bank, Department of Pathology (R.M.K.), and the Division of Hematology (J.M.C.), Brigham and Women's Hospital, and the Department of Medical Oncology, Dana-Farber Cancer Institute (E.P.A.) - all in Boston; and th
  • Alyea EP; From the Dana-Farber Cancer Institute at St. Elizabeth's Medical Center (C.I.C.), Blood Bank, Department of Pathology (R.M.K.), and the Division of Hematology (J.M.C.), Brigham and Women's Hospital, and the Department of Medical Oncology, Dana-Farber Cancer Institute (E.P.A.) - all in Boston; and th
  • Connors JM; From the Dana-Farber Cancer Institute at St. Elizabeth's Medical Center (C.I.C.), Blood Bank, Department of Pathology (R.M.K.), and the Division of Hematology (J.M.C.), Brigham and Women's Hospital, and the Department of Medical Oncology, Dana-Farber Cancer Institute (E.P.A.) - all in Boston; and th
N Engl J Med ; 379(19): 1846-1850, 2018 11 08.
Article in En | MEDLINE | ID: mdl-30403942
ABSTRACT
Daratumumab, a human IgG1κ monoclonal antibody targeting CD38, is used to treat multiple myeloma. We describe successful treatment with daratumumab in a case of treatment-refractory pure red-cell aplasia after ABO-mismatched allogeneic stem-cell transplantation. The patient was a 72-year-old man with the myelodysplastic syndrome who received a transplant from an HLA-matched, unrelated donor with a major ABO incompatibility (blood group A in the donor and blood group O in the recipient). The patient had persistent circulating anti-A antibodies and no red-cell recovery 200 days after transplantation. Standard treatments had no effect. Within 1 week after the initiation of treatment with daratumumab, he no longer required transfusions.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Blood Group Incompatibility / ABO Blood-Group System / Myelodysplastic Syndromes / Red-Cell Aplasia, Pure / Hematopoietic Stem Cell Transplantation / Immunologic Factors / Antibodies, Monoclonal Type of study: Etiology_studies Limits: Aged / Humans / Male Language: En Journal: N Engl J Med Year: 2018 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Blood Group Incompatibility / ABO Blood-Group System / Myelodysplastic Syndromes / Red-Cell Aplasia, Pure / Hematopoietic Stem Cell Transplantation / Immunologic Factors / Antibodies, Monoclonal Type of study: Etiology_studies Limits: Aged / Humans / Male Language: En Journal: N Engl J Med Year: 2018 Type: Article